ClinicalTrials.gg
RecruitingNCT06952348HYPERWALKUpdated Nov 12, 2026

HYPERtension Reduction Through WALKing Stairs Versus Brisk Walking

An interventional study of Stair and brisk walking combined and Brisk walking in Metabolic Disease, Cardiovascular Diseases and Hypertension, sponsored by Karolinska Institutet. Recruiting at 5 sites in Sweden. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Nov 12, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Metabolic Diseases with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Metabolic Diseases · Sweden.

Planned enrollment
3rd of 17
450 · median 71
Started
2025
with 2 others
No phase
5 of 21
3 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Karolinska Institutet

Among the 21 studies in Metabolic Diseases with a site in Sweden, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 21st registered.

Metabolic Diseases

765 studies on the registry are indexed under Metabolic Diseases; 194 are open to participants now.

Browse Metabolic Diseases studies →

Open to participants now

5 of the 21 studies in Metabolic Diseases with a site in Sweden are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 135 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 64 (47%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Metabolic Diseases with a site in Sweden, or all of them as a file.
02

Study summary

This clinical trial investigates whether incorporating stair walking into daily routines improves physical health in adults at risk of lifestyle-related conditions such as hypertension, type 2 diabetes, and cardiovascular disease. Participants will be randomized into three groups: (1) stair walking combined with brisk walking, (2) brisk walking alone, and (3) a control group receiving standard lifestyle advice without specific exercise instructions, stratified by age (\<65 y/o, v >=65) and site.

The primary objective is to assess whether the combination of stair and brisk walking leads to greater reductions in systolic blood pressure compared to brisk walking alone or standard care. Secondary outcomes include changes in cardiometabolic risk factors.

Participants in the stair walking group will be instructed to climb ≥250 steps per day (\~5.5 minutes/day or \~37.5 minutes/week), or complete an equivalent elevation via inclined slopes, along with ≥75 minutes of brisk walking per week. Those in the brisk walking group will walk ≥150 minutes per week. The control group will receive general lifestyle advice but no tailored physical activity goals or feedback.

Participants in both active groups will aim to double their baseline activity levels. Physical activity will be continuously monitored using wearable devices. The active groups will receive personalized feedback and motivational support throughout the 6-month intervention period.

If effective, this study may offer a simple, scalable, and low-cost intervention model for use in clinical and public health settings, emphasizing personalized goals, remote monitoring, and behavioral support.

03

Conditions studied

  • Metabolic Disease
  • Cardiovascular Diseases
  • Hypertension
  • Obesity and Overweight

Keywords

  • Cardiovascular prevention
  • Physical activity
  • Smart medicine
  • Obesity
  • Overweight
  • Hypertension
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Men and women aged 35 years or older with increased cardiometabolic risk, defined by all of the following:

  1. Clinically confirmed hypertension, with or without antihypertensive treatment, as documented in the Electronic Health Record (EHR).
  2. Overweight or obesity, defined as between 27 and 40.
  3. Physically inactive lifestyle, defined as either:

    • Light intensity or inactive category on the Stanford Brief Activity Survey (SBAS), or
    • Light intensity or inactive category in the physical activity section of the Swedish National Board of Health and Welfare Lifestyle Questionnaire.

Exclusion criteria

Exclusion Criteria

Medical to physical activity (based on FYSS 2021, p. 182):

  • Severe, symptomatic aortic stenosis
  • Acute pulmonary embolism, myocarditis, pericarditis, or systemic infection (e.g., fever, muscle pain, lymphadenopathy)
  • Suspected or known aortic dissection
  • Severe hypertension (Grade 3: SBP >180 mmHg or DBP >110 mmHg), regardless of symptoms
  • Unstable coronary artery disease (including unstable angina, suboptimally treated stable angina, or recent myocardial infarction \<8 weeks)
  • Symptomatic, uncontrolled arrhythmia
  • Symptomatic, uncontrolled heart failure

Other exclusion criteria:

  • Implanted pacemaker or ICD
  • Pregnancy
  • Smartphone incompatibility with Fitrockr© app (iOS \<16 or Android OS \<10)
  • Inability to understand Swedish or English
  • Any condition that may interfere with protocol compliance (e.g., severe mental illness or cognitive impairment)
  • Inability to walk stairs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Stair and brisk walking combined

    Participants will double their baseline physical activity levels by combining stair walking and brisk walking. The stair walking goal is ≥250 steps per day (equivalent to \~37.5-45 meters elevation or 15 floor levels), totaling \~37.5 minutes per week. In addition, they will complete ≥75 minutes of brisk walking per week.

    Behavioral: Stair and brisk walking combined

  • Experimental
    Brisk walking

    Participants will double their baseline physical activity levels by engaging in brisk walking only, with a minimum target of \>150 minutes per week.

    Behavioral: Brisk walking

  • Active comparator
    Standard care

    Participants will receive general lifestyle advice aligned with current physical activity guidelines but will not be provided with specific exercise instructions, personalized activity targets, or feedback. They will wear the same activity monitor as the intervention groups, but without access to feedback or goal-setting features.

    Behavioral: Standard care

Interventions

  • BehavioralStair and brisk walking combined

    See arms.

  • BehavioralBrisk walking

    See arms.

  • BehavioralStandard care

    See arms.

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure (SBP) at 6 months

    Office systolic blood pressure (SBP) at 6-month follow-up, adjusted for baseline values. SBP is a validated and widely accepted surrogate marker for cardiovascular morbidity and mortality, as well as overall health risk.

    Time frame: 6 months

Secondary outcomes

  1. Diastolic Blood Pressure (DBP)

    Office diastolic blood pressure (DBP) at 6-month follow-up, adjusted for baseline values. DBP is a clinically relevant indicator of cardiovascular risk and contributes to the assessment of overall blood pressure control.

    Time frame: 6 months

  2. HOMA-index

    Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 6-month follow-up, adjusted for baseline values. HOMA-IR is a validated surrogate marker of insulin resistance and metabolic risk, commonly used in cardiometabolic research.

    Time frame: 6 months

  3. HbA1c

    Hemoglobin A1c (HbA1c) at 6-month follow-up, adjusted for baseline values. HbA1c reflects average blood glucose levels over the preceding 2-3 months and is a standard marker for assessing glycemic control and diabetes risk.

    Time frame: 6 months

  4. LDL cholesterol

    Low-Density Lipoprotein (LDL) cholesterol at 6-month follow-up, adjusted for baseline values. LDL cholesterol is a key biomarker for cardiovascular risk and a primary target in lipid-lowering therapies.

    Time frame: 6 months

  5. Triglycerides

    Triglycerides (TG) at 6-month follow-up, adjusted for baseline levels. Elevated TG are associated with increased cardiovascular risk and are a core component of the metabolic syndrome.

    Time frame: 6 months

07

Study locations

4 of 5 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Blood pressure (systolic and diastolic), BMI, sex, age, HOMA-index, HbA1c, Triglycerides, LDL will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.

Of 183 non-industry interventional studies with no phase under Metabolic Diseases, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 31 months is above that.

Counting every sponsor, half of 202 studies reached it within 22 months; a quarter within 10 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2028 → Jun 2028 and completion May 2029 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
Apr 30, 2025
StartActual
Nov 27, 2025
Primary completionEst.
Jun 2028was Dec 2028
CompletionEst.
Dec 2028was May 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Södersjukhuset · Stockholm, SwedenNot yet recruiting→Recruiting
  • Södertälje sjukhus · Stockholm, SwedenNot yet recruiting→Recruiting
Show site
  • Boo Primary Care Center · Stockholm, Sweden
Nov 12, 2026
Primary completion
Dec 2028→Jun 2028
Nov 12, 2026
Study completion
May 2029→Dec 2028
Nov 12, 2026
Contact
Study contact changed: added p•••@ki.se. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Södersjukhuset · Stockholm, SwedenNot yet recruiting→Recruiting
    • Södertälje sjukhus · Stockholm, SwedenNot yet recruiting→Recruiting
    Show site
    • Boo Primary Care Center · Stockholm, Sweden
    Primary completion Dec 2028→Jun 2028
    Study completion May 2029→Dec 2028
    Contact Study contact changed: added p•••@ki.se. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06952348
Collaborators
Stockholm South General Hospital, Ersta Cardiology Outpatient Clinic, Liljeholmens vårdcentral, Boo vårdcentral, Karolinska University Hospital, Sodertalje Hospital
Responsible party
Pontus Andell (Associate Professor, Consultant in Cardiology, Karolinska Institutet) — Principal investigator
First posted
Apr 30, 2025
Start date
Nov 27, 2025
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Carl Johan Sundberg
Contact
carl.j.sundberg@ki.se
0046852480000
Pontus Andell, MD, PhD
Contact
pontus.andell@ki.se

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion